Stockscreener 앱 받기
223.06
0.29%
-0.64
시장 영업 전:
220.02
-3.04
-1.36%
Axsome Therapeutics Inc 주식(AXSM)의 최신 뉴스
Mark Jacobson Sells 4,517 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat
Insider Selling: Axsome Therapeutics (NASDAQ:AXSM) COO Sells 233 Shares of Stock - MarketBeat
Axsome Therapeutics COO Mark Jacobson sells $1.08m in stock - Investing.com
Axsome Therapeutics COO Mark Jacobson sells $1.08m in stock By Investing.com - Investing.com UK
Axsome Therapeutics (AXSM) reports Q1 loss, beats revenue estimates - MSN
AXSM Q1 Loss Widens, Revenues Jump on Higher Auvelity Sales - Yahoo Finance UK
Axsome Therapeutics (NASDAQ:AXSM) Stock Price Expected to Rise, Morgan Stanley Analyst Says - MarketBeat
Strong Drug Sales Lift Axsome Revenue, But Profit Miss Drags Stock - Sahm
Axsome Therapeutics Reports Strong Q1 2026 Results Driven by Revenue Growth and FDA Approval for AUVELITY - IndexBox
Wells Fargo & Company Boosts Axsome Therapeutics (NASDAQ:AXSM) Price Target to $255.00 - MarketBeat
Robert W. Baird Issues Positive Forecast for Axsome Therapeutics (NASDAQ:AXSM) Stock Price - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $310.00 at Mizuho - MarketBeat
B. Riley Adjusts Price Target on Axsome Therapeutics to $300 From $230, Maintains Buy Rating - marketscreener.com
Mizuho Adjusts Price Target on Axsome Therapeutics to $310 From $228, Maintains Outperform Rating - marketscreener.com
Axsome Therapeutics, Inc. $AXSM Shares Bought by UBS Group AG - MarketBeat
RBC Raises Price Target on Axsome Therapeutics to $302 From $242, Keeps Outperform Rating - marketscreener.com
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2026 Earnings Call Transcript - Insider Monkey
Axsome Therapeutics 1Q Rev $191.2M >AXSM - Moomoo
Axsome Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Mizuho raises Axsome Therapeutics price target on Auvelity outlook - Investing.com
Mizuho raises Axsome Therapeutics price target on Auvelity outlook By Investing.com - Investing.com Canada
Axsome Wins FDA Nod For Expanded Use For Auvelity Beyond Depression - Sahm
B.Riley raises Axsome Therapeutics price target on sales guidance - Investing.com
B.Riley raises Axsome Therapeutics price target on sales guidance By Investing.com - Investing.com Canada
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Axsome Therapeutics 1Q Auvelity Net Product Sales $153.2M, Up 59% >AXSM - Moomoo
Axsome Therapeutics Earnings Call Signals Aggressive Growth - TipRanks
RBC Capital raises Axsome stock price target on higher revenue outlook By Investing.com - Investing.com South Africa
Axsome Therapeutics Q1 2026 earnings preview - MSN
Axsome projects Auvelity peak sales of at least $8B following Alzheimer's agitation approval and June launch - MSN
Baird raises Axsome Therapeutics stock price target on Auvelity launch By Investing.com - Investing.com Australia
AXSM Stock Is Rising Today After Wall Street’s Positive Stance Despite Mixed Q1 – What's Behind The Optimism? - Stocktwits
Axsome Therapeutics, Inc. 1Q 2026: Revenue $191.2M, EPS $(1.26) — 10-Q Summary - TradingView
Baird raises Axsome Therapeutics stock price target on Auvelity launch - Investing.com
RBC Capital raises Axsome stock price target on higher revenue outlook - Investing.com
Oppenheimer raises Axsome Therapeutics price target on Auvelity sales By Investing.com - Investing.com Australia
Axsome Therapeutics Reports Wider Than Expected Q1 2026 Loss - AlphaStreet
Oppenheimer raises Axsome Therapeutics price target on Auvelity sales - Investing.com
Why Did Axsome Therapeutics Stock Hit Another Record High Today? - The Globe and Mail
Axsome Therapeutics Inc Stock (AXSM) Moved Up by 10.20% on May 4: Facts Behind the Movement - TradingKey
Guggenheim raises Axsome stock price target to $260 on drug sales - Investing.com
AXSM Stock Jumps As FDA Clears Auvelity For Alzheimer’s Agitation - StocksToTrade
Axsome Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Axsome Q1 2026 slides: 57% revenue growth amid FDA approval milestone - Investing.com India
Axsome Therapeutics: Current Cash Sufficient to Fund Anticipated Operations Into Cash Flow Positivity >AXSM - Moomoo
Axsome Therapeutics 1Q Loss/Shr $1.26 >AXSM - Moomoo
TD Cowen raises Axsome stock price target on strong Q1 results By Investing.com - Investing.com South Africa
TD Cowen raises Axsome stock price target on strong Q1 results - Investing.com
Axsome Therapeutics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Axsome Therapeutics Q1 2026 Earnings Review: Gains Mystify Me, But Can't Be Denied (AXSM) - Seeking Alpha
Why is Axsome therapeutics trending amid Nasdaq Composite Index gains? - Kalkine Media
AXSM: Q1 revenue up 57% YoY, Auvelity FDA-approved for Alzheimer's agitation, peak sales outlook raised - TradingView
Axsome Therapeutics Reports 57% Revenue Growth in Q1 2026 and Expands CNS Drug Pipeline with New FDA Approvals - Minichart
AXSM Stock Surges As FDA Clears Auvelity In Alzheimer’s Agitation - timothysykes.com
H.C. Wainwright raises Axsome stock price target on FDA approval By Investing.com - Investing.com South Africa
AXSM: Q1 revenue up 57%, Auvelity FDA-approved for Alzheimer's agitation, peak sales outlook raised - TradingView
H.C. Wainwright raises Axsome stock price target on FDA approval - Investing.com UK
Axsome Therapeutics Q1 Earnings Call Highlights - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Reaches New 12-Month High Following Analyst Upgrade - MarketBeat
Earnings call transcript: Axsome Therapeutics Q1 2026 misses forecasts - Investing.com
Earnings call transcript: Axsome Therapeutics Q1 2026 misses forecasts By Investing.com - Investing.com India
Axsome Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Here's What Key Metrics Tell Us About Axsome (AXSM) Q1 Earnings - Yahoo Finance
Axsome Therapeutics Q1 2026 Earnings Call: Complete Transcript - Benzinga
Axsome Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Axsome Therapeutics, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:AXSM) 2026-05-04 - Seeking Alpha
0.14%
0.48%
자본화:
|
볼륨(24시간):